NCT02712723 - Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

August 27, 2018

Study Completion Date

April 30, 2023

Conditions

Breast Cancer

Interventions

DRUG

Letrozole

Nonsteroidal aromatase inhibitor

DRUG

Ribociclib

Oral cyclin-dependent kinase (CDK) inhibitor

DRUG

Placebo

Placebo for ribociclib

Trial Locations (13)

10032

Columbia University Medical Center, New York

33442

University of Miami Sylvester Comprehensive Cancer Center, Deerfield Beach

53705

University of Wisconsin Carbone Cancer Center, Madison

64064

University of Kansas Cancer Center - Lee's Summit, Lee's Summit

64131

University of Kansas Cancer Center - South, Kansas City

64154

University of Kansas Cancer Center - North, Kansas City

66112

University of Kansas Cancer Center - West, Kansas City

66205

University of Kansas Cancer Center - Westwood, Westwood

66210

University of Kansas Cancer Center - Overland Park, Overland Park

72205

University of Arkansas for Medical Sciences, Little Rock

91010

City of Hope National Medical Center, Duarte

92705

Cancer Research Collaboration, Santa Ana

02114

Massachusetts General Hospital, Boston